Hoppa till innehåll
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avancerad
  • CIELO: a randomized, double-bl...
  • Hänvisa
  • Textmeddelande
  • Skicka per e-post
  • Skriv ut
  • Exportera posten
    • Exportera till: RefWorks
    • Exportera till: EndNoteWeb
    • Exportera till: EndNote
  • Permanent länk
CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis

CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis

Bibliografiska uppgifter
Huvudupphovsmän: Gelfand, JM, Abboud, H, Irani, SR, Nakajima, H, Piquet, A, Pittock, SJ, Yeh, EA, Overell, J, Rajan, S, El-Khairi, M, Lee, S-T
Materialtyp: Conference item
Språk:English
Publicerad: Wiley 2022
  • Beståndsuppgifter
  • Beskrivning
  • Liknande verk
  • Katalogiseringsuppgifter

Liknande verk

  • Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
    av: Lee, S, et al.
    Publicerad: (2024)
  • Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
    av: Soon-Tae Lee, et al.
    Publicerad: (2024-08-01)
  • CSF Findings in Chinese Patients with NMDAR, LGI1 and GABABR Antibody-Associated Encephalitis
    av: Qiao S, et al.
    Publicerad: (2024-03-01)
  • Comprehensive B-Cell Immune Repertoire Analysis of Anti-NMDAR Encephalitis and Anti-LGI1 Encephalitis
    av: Jingjing Feng, et al.
    Publicerad: (2021-10-01)
  • Seizures and risk of epilepsy in anti‐NMDAR, anti‐LGI1, and anti‐GABABR encephalitis
    av: Chun‐Hong Shen, et al.
    Publicerad: (2020-08-01)

Sökalternativ

  • Sökhistorik
  • Avancerad sökning

Sök mera

  • Bläddra i katalogen
  • Bläddra alfabetiskt
  • Utforska kanaler
  • Kursböcker
  • Nytt i katalogen

Behöver du hjälp?

  • Söktips
  • Fråga biblioteket
  • Vanliga frågor